Question-and-Answer Session
Operator
Thank you. We will now conduct a question-and-answer session. (Operator Instructions) Our first question comes from Randall Stanicky with Goldman Sachs; please state your question.
Randall Stanicky - Goldman Sachs
Great, thanks guys. Just one question and then a follow-up, Shlomo, based on your comments today around M&A, should we read that to see any change in your interest in either generic versus a brand deal or the size of potential deal?
Shlomo Yanai
No, my message was actually nothing has been changed. Our strategy is as I explain many times that our major business is India, generic arena. This is where we see more potential to growth. We have in addition a very interesting and very profitable branded business, which we NIOSH and going to grow as well and a lot of important things of how we are evaluating and how we are targeting and later how we are integrating the acquisition and Teva is an accretive company, we’ll continue to acquire companies in due time, so I don’t want to raise any speculation on any other kind of misunderstanding about the Teva future.
Randall Stanicky - Goldman Sachs
Okay, fair enough. Then a follow up that maybe for Eyal, on the lines in the R&D spending in general, how do you think about the JV investment and in the reimbursement that line items down ran a little bit from the last quarter to this quarter. So, as we think about modeling over the next several quarters how should we think about the contribution from those two angles?
Eyal Desheh
This quarter, we had a much smaller reimbursement was about $8 million, which reduced our R&D expenses quarterly as far as I know there’s nothing much left from these reimbursement and everything in the future will be done jointly by the contribution for the two companies equally, the last of the two statements.
Randall Stanicky - Goldman Sachs
So, how much should we expect you to contribute to the JV going forward on a quarterly basis?
Eyal Desheh
In terms of our investment and our share investment by view I repeat the question I don’t think that we ever communicated on a product line by product line level, but on an annual basis we’re talking about tens of millions of dollars, not hundreds.
Randall Stanicky - Goldman Sachs
Okay, thank you.
Operator
Our next question comes from Scott Hirsch with Credit Suisse; please state your question.
- To read the full transcript on Seeking Alpha, click here »
